Clearside Biomedical (CLSD) Misses Q2 EPS by 1c

Clearside Biomedical (NASDAQ: CLSD) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.02 million versus the consensus estimate of $111.83 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c